Table 1 Clinical characteristics of stage I to III endometrial cancer patients stratified by lymph node status
Characteristics | Total N = 874 | LNM | P value | |
|---|---|---|---|---|
No N = 792 (90.62) | Yes N = 82 (9.38) | |||
Age at surgery (years) | 53.58 ± 0.40 | 53.74 ± 0.42 | 51.79 ± 1.53 | 0.24 |
Pathological type | 0.01 | |||
Endometrioid | 760 (86.96) | 702 (88.64) | 58 (70.73) | |
Non-endometroid | 114 (13.04) | 90 (11.36) | 24 (29.27) | |
FIGO stage | < 0.01 | |||
I | 570 (65.22) | 570 (71.97) | 0 | |
II | 212 (24.26) | 212 (26.77) | 0 | |
III | 92 (10.52) | 10 (1.26) | 82 (100) | |
Tumor grade | 0.04 | |||
1 | 240 (27.46) | 224 (28.28) | 16 (19.51) | |
2 | 438 (50.14) | 398 (50.25) | 34 (41.46) | |
3 | 196 (22.40) | 170 (21.57) | 32 (39.03) | |
Myometrial invasion | < 0.01 | |||
< 50% | 586 (67.05) | 548 (69.19) | 38 (46.34) | |
≥ 50% | 288 (32.95) | 244 (30.81) | 44 (53.66) | |
Primary tumor diameter | 0.26 | |||
< 2 | 100 (11.44) | 96 (12.12) | 4 (4.88) | |
≥ 2 | 774 (88.36) | 696 (87.88) | 78 (95.12) | |
Cervical stromal invasion | < 0.01 | |||
No | 604 (69.11) | 576 (72.73) | 28 (34.15) | |
Yes | 270 (30.89) | 216 (27.17) | 54 (65.85) | |
LVSI | < 0.01 | |||
No | 736 (84.21) | 716 (90.40) | 48 (58.54) | |
Yes | 138 (15.79) | 76 (9.60) | 34 (41.46) | |
Ascites | 0.49 | |||
No | 736 (84.21) | 670 (84.60) | 66 (80.49) | |
Yes | 138 (15.79) | 122 (15.40) | 16 (19.51) | |
Ovarian metastasis | < 0.01 | |||
No | 850 (97.25) | 782 (98.74) | 68 (82.93) | |
Yes | 24 (2.75) | 10 (1.26) | 14 (17.07) | |
Preoperative CA125 | 24.45 (27.70) | 23.19 (26.52) | 41.53 (56.46) | < 0.01 |
Lymphadenectomy | 0.61 | |||
Only pelvic | 530 (60.64) | 478 (60.35) | 52 (63.41) | |
Pelvic + paraaortic | 320 (36.61) | 294 (37.12) | 26 (31.71) | |
Paraaortic sampling | 24 (2.75) | 20 (2.53) | 4 (4.88) | |
Median number of LNs removed, n (range) | 13 (10–65) | 13 (10–65) | 13 (10–33) | 0.83 |
Number of pelvic LNs removed | 13 (10–46) | 13 (10–46) | 11 (10–33) | 0.17 |
Number of paraoartic LNs removed | 3 (0–23) | 3 (0–23) | 3 (0–11) | 0.11 |
Lymph node metastasis | ||||
Pelvic LN metastasis only | – | – | 74 (90.24) | |
PALN metastasis only | 0 | |||
Pelvic and PALN metastasis | 8 (9.76) | |||
Status | < 0.01 | |||
Alive | 790 (90.39) | 748 (94.44) | 42 (51.22) | |
Died | 84 (9.61) | 44 (5.56) | 40 (48.78) | |
Follow-up, month (range) | 59.3 (5–108.5) | 59.5 (5–108.5) | 56.6 (8.3–108) | 0.96 |
Adjuvant therapy | 0.03 | |||
No | 748 (85.58) | 690 (87.12) | 58 (70.73) | |
Chemotherapy only | 94 (10.76) | 74 (9.34) | 20 (24.39) | |
Radiotherapy only | 28 (3.20) | 24 (3.03) | 4 (4.88) | |
Both | 4 (0.46) | 4 (0.51) | 0 | |